Objective-The ability of high-density lipoprotein (HDL) to remove cholesterol from atherosclerotic plaque is thought to underlie its inverse correlation with cardiovascular risk. Our objective was to produce and characterize a human apolipoprotein AI (apoA-I) product optimized to treat clinical atherosclerotic disease. Approach and Results-A new formulation of full length, plasma-derived human apoA-I termed CSL112 was designed to maximize the cholesterol efflux from cells and exhibit favorable pharmacological properties. CSL112 is a disc-shaped particle that strongly elevates cholesterol esterification and shows good pharmacokinetics in rabbits. Infusion of CSL112 into rabbits caused a strong and immediate increase in the ATP binding cassette transporter A1 (ABCA1)-dependent efflux capacity of plasma, an increase in plasma unesterified cholesterol and rapid subsequent cholesterol esterification. In the presence of human plasma, CSL112 was significantly more potent than native HDL at enhancing cholesterol efflux from macrophages, and the efflux elevation was predominantly via the ABCA1 transporter. Consistent with this observation, addition of CSL112 to plasma led to generation of high levels of HDL-VS, a favorable substrate for ABCA1. The lipid profile of plasma did not affect these behaviors. In studies with whole human blood, CSL112 reduced expression of intercellular adhesion molecule 1 and cytokine secretion, and as with cholesterol efflux, these activities were substantially greater than those of native HDL assayed in parallel. Conclusions-CSL112 has favorable pharmacological properties and strongly elevates the ability of plasma to withdraw cholesterol from cells. Preferential elevation of ABCA1-dependent efflux may target atherosclerotic plaque for cholesterol removal and this property makes CSL112 a promising candidate therapy for acute coronary syndrome. (Arterioscler Thromb Vasc Biol. 2013;33:2202-2211.)
C holesterol in coronary arteries builds up over decades and may eventuate in acute coronary syndrome (ACS). Current medical therapy for ACS focuses on opening of severely stenotic coronary segments with percutaneous coronary intervention and on antiplatelet drugs to reduce arterial thrombosis. Despite optimal current therapy, ACS patients experience an extremely high rate of recurrent ACS in the period immediately after an index ACS. For example, in a recent trial 12% of patients experienced recurrent ACS in the first year, with nearly half of the events occurring in the first 30 days. 1 A potential explanation for this high rate is that neither percutaneous coronary intervention nor antiplatelet drugs act on the ultimate cause of coronary disease, plaque cholesterol.
Apolipoprotein AI (ApoA-I) is known to transport cholesterol out of cholesterol-loaded tissues, 2 and recent studies indicate that this transport can be extremely rapid. 3 On the basis of the in vitro rate of net cholesterol efflux from cholesterol-loaded macrophages to high-density lipoprotein (HDL) , 4 it can be calculated that a foam cell carrying 50% by weight cholesterol can efflux half of the load in 1 week. Studies in animals suggest that even faster efflux may be observed; correcting dyslipidemia in apoE −/− mice with an adenoviral vector caused loss of ≈75% of plaque cholesterol in 1 week, 5 and transplanting atherosclerotic plaques from apoE −/− mice to wild-type recipients caused loss of ≈65% of plaque cholesterol ester in 1 week. 6 Importantly, Feig et al 6 showed that apoA-I is necessary for this rapid reduction, that a high apoA-I level is effective even in the presence of sustained high levels of apoB-containing lipoproteins, and that foam cell emigration from the plaque may contribute to the rapid loss. Similar results have been obtained on infusion of apoA-I in animals or in human subjects. Two infusions of apoA-I Milano into rabbits caused the loss of ≈50% of plaque cholesterol in 8 days, 7 and a single infusion of reconstituted HDL caused loss of ≈60% of cholesterol ester in femoral plaque in 5 to 7 days. 8 The ability of infused apoA-I to remove half of plaque cholesterol in a week suggests that it may act quickly enough to affect the high recurrent cardiovascular event rate seen in the month after ACS.
Because of its promise in treatment of ACS, infused HDL therapy has been long pursued by the pharmaceutical industry. 9, 10 Here, we describe a novel formulation of human apoA-I (hApoA-I) intended to treat ACS. This formulation, termed CSL112, was designed to optimize cholesterol efflux by ATP binding cassette transporter A1 (ABCA1), a transporter induced by excess cellular cholesterol and present in atherosclerotic plaque. 11, 12 Although CSL112 acted as a good substrate for ABCA1 in tissue culture, we found adding CSL112 to human plasma caused a more dramatic rise in ABCA1-dependent efflux capacity with activity substantially greater than that of native HDL from plasma. We propose that CSL112 is rapidly remodeled in plasma to a form that can accept cholesterol from ABCA1. We support this hypothesis with studies showing that adding CSL112 to plasma results in rapid and profound elevation of very small HDL (HDL-VS) by the nomenclature of Rosenson et al, 13 also referred to as PreBeta1, the preferred substrate for ABCA1. 13
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Infusion of CSL112 Removes Cholesterol From Tissues
Prior work has shown that infusion of therapeutic amounts of pure apoA-I in man resulted in rapid clearance with a halflife of ≈2 hours. 14 However, reconstitution of the apoA-I with phosphatidylcholine (PC) resulted in a volume of distribution and clearance rate comparable with endogenous apoA-I (half-life, 3-4 days). 15 The formulation chosen for CSL112 thus used reconstitution with PC. A molar ratio of 55 PC per 1 apoA-I yielded a population of particles which elute in a single symmetrical peak from size exclusion chromatography column with a slightly higher retention time than native HDL ( Figure 1A) . The particles had a hydrodynamic diameter of 7.5 to 8.0 nm by nondenaturing gel electrophoresis ( Figure 1B ) and were disc shaped by negative stain electron and cryo-electron microscopy ( Figure 1C ). Size heterogeneity in native gels with 2 apparent subpopulations in the 7.5 to 8.5 nm range has been seen in prior studies with reconstituted HDL and has been attributed to a subset of particles with apoA-I folds or hairpins that accommodate quantized expansion with addition of lipid. 16, 17 Rouleaux were clearly seen in negative stain images, and the particles in rouleaux had a diameter of 9.8±2.9 nm and height of 3.2±0.6 nm ( Figure 1D ). These dimensions may be biased toward larger diameters as larger discs are more often found in rouleaux. Chemical crosslinking studies demonstrated 2 apoA-I molecules per particle (not shown). The molecular size calculated on the basis of the deduced stoichiometry (2 apoA-I and 110 PC) is 144 kDa, a value consistent with our gel-based, chromatography-based, and electron microscopy-based measures.
Favorable pharmacokinetic behavior of CSL112 was confirmed by infusing 75 mg/kg into rabbits. Levels of hApoA-I in the plasma reached maximum by the end of the infusion period (0.7 hours), then steadily declined, with half of the infused hApoA-I still present in the circulation at 8 hours post infusion ( Figure 2A ). By comparison, lipid-free apoA-I was cleared much more quickly ( Figure IIIA in the online-only Data Supplement). The infused CSL112 rapidly withdrew cholesterol from tissues as evidenced by a rise in plasma total Figure 2 . Human apolipoprotein AI (hApoA-I) pharmacokinetic profile, lecithin cholesterol acyltransferase (LCAT) activation, cholesterol efflux, and particle remodeling after the infusion of CSL112 into rabbits. CSL112 was administered to rabbits intravenously (dose 75 mg/kg, >0.7 h). Blood was collected at different time intervals post infusion as indicated. A, hApoA-I content in rabbit plasma was measured by ELISA (Mabtech). hApoA-I concentration values represent the mean±SD for 8 animals. ****P<0.0001 (n=8) compared with baseline value (pre infusion). B, Total and unesterified cholesterol were measured in rabbit plasma and corresponding apoB-depleted fraction (obtained after precipitation of plasma apoB lipoproteins with polyethyleneglycol [PEG]) using high-density lipoprotein (HDL) and low-density lipoprotein/ very-low-density lipoprotein Cholesterol Quantification Kit (MBL International). Values are mean±SD. ****P<0.0001, ***P<0.0005 (n=8) compared with baseline values (pre infusion). C, To measure LCAT activity, plasma samples of rabbits treated with CSL112 were equilibrated with [ 14 C]-cholesterol (7.5 nmol/L per milliliter) for 4 h at 4°C. Cholesterol esterification was measured as described in Materials and Methods in the online-only Data Supplement. LCAT activity is presented as percentage change from baseline levels detected in preinfused rabbit plasma (t=0). Each value shows the mean±SD of 5 animals. ***P<0.0002, **P<0.01, and *P<0.05 (n=5) compared with baseline values (pre infusion). D, CSL112 preferentially enhances ABCA1-dependent efflux ex vivo. Cholesterol efflux from RAW264.7 macrophages to whole and apoB-depleted plasma of rabbits dosed with CSL112. Before initiation of efflux, RAW264.7 cells were loaded with free [ 3 H]cholesterol for 36 h and stimulated with 0.3 mmol/L 8Br-cAMP for 16 h to upregulate ABCA1. Efflux was promoted by incubating the [ 3 H]cholesterollabeled RAW264.7 cells with each individual rabbit plasma sample at a final concentration of 0.5%. Each fractional efflux value represents the mean±SD of 6 animals in 2 groups treated with CSL112 was measured. Total efflux was measured from 8Br-cAMP-stimulated cells. The difference in efflux between stimulated and nonstimulated cells is a measure of ABCA1-mediated efflux. ****P<0.0001, ***P<0.001, and **P<0.005 (n=6) compared with baseline values (pre infusion). E, Dynamic remodeling of CSL112 after infusion into rabbits. Plasma samples of rabbits infused with CSL112 were subjected to nondenaturing gel electrophoresis on gradient 4% to 30% polyacrylamide gels followed by Western blot analysis of hApoA-I. Time (h) after infusion is indicated above the lanes. Distribution of hApoA-I among HDL subfractions before (whole plasma) and after (apoB-depleted plasma) precipitation of apoB-containing lipoproteins is shown. CSL112 used for infusion into rabbits was included in the analysis as control (CSL112). Molecular size markers (diameter in nm) and position of rabbit HDL are indicated. cholesterol ( Figure 2B ). Almost all the increment in plasma cholesterol was found in the HDL fraction ( Figure 2B ), with little change in non-HDL (not shown). Elevation of HDL total cholesterol was driven by a rapid increase in unesterified cholesterol (0.7 hours) followed by a concomitant decline in unesterified cholesterol (2-8 hours) and a rise of cholesteryl ester (2-8 hours; Figure 2B ). To confirm our hypothesis that the rise of plasma HDL cholesteryl ester is caused by elevated lecithin cholesterol acyltransferase (LCAT) activity, we measured rates of cholesterol esterification in pre-and postinfused animal plasma ex vivo. Figure 2C demonstrates that infusion of CSL112 into rabbits results in an immediate ≈1.7fold increase of plasma LCAT activity which was sustained for 8 hours. Taken together, these data suggest that infused CSL112 augments mobilization of unesterified cholesterol from peripheral tissues to plasma HDL and elevates the rate of ongoing cholesterol esterification.
CSL112 Elevates Capacity of Plasma to Support Cholesterol Efflux From Cells
To characterize the net movement of cholesterol from tissue into plasma, we measured the capacity of postinfused rabbit plasma to support cholesterol efflux from RAW264.7 mouse macrophages ex vivo. Because cholesterol-loaded cells, such as those in an atherosclerotic plaque, express ABCA1, 12 the contribution of this transporter to efflux was measured in RAW cells stimulated with 8Br-cAMP. CSL112 caused an immediate rise (≈3-fold) of the capacity of whole and apoB-depleted plasma to efflux cholesterol ( Figure 2D ). The magnitude of the rise in efflux was larger than expected given that the infusion was designed to cause less than double plasma apoA-I. More surprising was the magnitude of the elevation of ABCA1-dependent efflux which showed a >10-fold elevation ( Figure 2D ).
To explore the mechanism for the dramatic elevation in ABCA1-dependent efflux, we used nondenaturing gels to separate lipoproteins from rabbits dosed with CSL112 ( Figure 2E ). These studies took advantage of the fact that hApoA-I can be specifically identified on blots with an antibody that does not recognize rabbit apoA-I. We observed an identical pattern of distribution of hApoA-I among lipoproteins in rabbit whole plasma and in the HDL fraction prepared from plasma by polyethyleneglycol precipitation indicating that after infusion of CSL112, hApoA-I is not associated with apoB-containing lipoproteins. However, it was clear that CSL112 underwent a prompt remodeling on infusion. By 2 hours after the start of infusion, the majority of hApoA-I was seen in particles much larger than parent CSL112. The size of these particles was ≈10 nm at 2 hours and declined slightly at 4 and 8 hours. This range is comparable with endogenous rabbit HDL (9.6-10 nm). 18 Smaller species of hApoA-I were also seen during remodeling. A species slightly smaller than parent CSL112 (7.1-7.6 nm) was seen at 0.7 and 2 hours, and a second, much smaller species of a size comparable with HDL-VS (5.6 nm) peaked after 4 hours but was sustained for the duration of the study. The infusion of CSL112 into rabbits thus seemed to result in sequential formation of large forms of HDL similar to large HDL (HDL-L) and very large HDL (HDL-VL), small forms similar to HDL-VS (5.6 nm) and finally larger forms similar to the dominant HDL species of rabbit. The time course of appearance of low molecular weight particle species containing hApoA-I coincided roughly with the rise in ABCA1-dependent cholesterol efflux to plasma ( Figure 2D and 2E) , whereas time-dependent accumulation of larger particles (10-12 nm) was consistent with the observed increase in cholesterol esterification and reduced efflux capacity ( Figure 2D and 2E ). We note that drawing a correlation between structure and efflux activity must take into account remodeling of HDL that will occur during the 5-hour incubation with the cholesterol-loaded cells. Thus, peak efflux was observed in samples drawn at 0.7 hours and incubated with cells for 5 hours, whereas maximal abundance of lipid-poor apoA-I was seen in blood samples drawn at 4 hours. Because lipid-poor forms of apoA-I, such as HDL-VS, 13, 19 are the preferred substrates for ABCA1, the remodeling observed may explain the exaggerated elevation of ABCA1-dependent efflux on CSL112 infusion.
Addition of CSL112 to Human Plasma Yields HDL-VS and Dramatically Potentiates ABCA1-Dependent Cholesterol Efflux
To quantitatively explore apoA-I behavior using conditions closer to those in the clinic, we characterized functional changes on incubation of CSL112 with human plasma and serum ex vivo. CSL112 was spiked into sera derived from 5 individuals with a range of lipid phenotypes ( Table I in the online-only Data Supplement), incubated at 37°C for 1 hour, and cholesterol efflux to serum was evaluated using J774 cells. Addition of CSL112 increased global efflux to serum in all samples, regardless of lipid profile ( Figure 3A ). As observed for rabbit samples, the increase in global efflux was mainly driven by an increase of the ABCA1-dependent efflux, whereas ABCA1-independent efflux was more modestly affected ( Figure 3A) . To further quantify the large increase in efflux after addition of CSL112 to serum, the contributions of endogenous and exogenous apoA-I to cholesterol efflux were normalized to levels of apoA-I ( Figure 3B ). Per milligram per milliliter of apoA-I, CSL112 was 3.4-fold more efficacious in promoting global cholesterol efflux from macrophages than endogenous apoA-I ( Figure 3B, left) . The enhanced efficacy of CSL112 versus endogenous apoA-I and CSL112 was all attributable to ABCA1-dependent efflux; per milligram per milliliter of apoA-I, CSL112 was 16-fold more efficacious than endogenous apoA-I at promoting ABCA1-dependent efflux (Figure 3B, right) .
To further characterize the efflux capacity of CSL112, native HDL and apoA-I were used for direct comparison. When tested alone, CSL112 and native HDL caused comparable efflux from RAW264.7 macrophages ( Figure 4A , compound alone panels). However, when CSL112 and native HDL were incubated with fresh human plasma for ≥1 hour, CSL112 was significantly more potent (2-3 fold) at enhancing ABCA1dependent efflux to plasma than native HDL ( Figure 4A , middle and right, Donors 1 and 2). The ABCA1-dependent efflux induced by CSL112 approached but was always less than that caused by apoA-I, whether assayed alone or after incubation with plasma.
In rabbits, elevated ABCA1-dependent cholesterol efflux correlated with elevated levels of HDL-VS by native gel (Figure 2E ). To examine whether elevation of the plasma cholesterol efflux capacity induced by CSL112 in human plasma shows similar correlation, HDL-VS levels were measured by ELISA. CSL112 and native HDL both exhibited very low levels of HDL-VS ( Figure 4B , Donors 1 and 2). However, incubation of CSL112 with plasma caused a sharp and sustained elevation of HDL-VS. In contrast, native HDL induced only a slight and transient increase of the normally low levels HDL-VS levels in plasma, and addition of apoA-I leads to high and constant levels of HDL-VS ( Figure 4B ). The levels of HDL-VS achieved on incubation with plasma correlated well with changes in the capacity of plasma to support ABCA1-dependent cholesterol efflux; CSL112 generated roughly half of the HDL-VS levels induced by apoA-I and elevated ABCA1-dependent efflux roughly half as much as apoA-I. This finding is consistent with HDL-VS being responsible for the elevated capacity of plasma to induce cholesterol efflux via ABCA1 and suggests that similar effects might be observed on CSL112 infusion into humans in vivo.
To more directly examine the effects of CSL112, native HDL, and apoA-I on HDL particle size distribution in human plasma, HDL fractions prepared by polyethyleneglycol precipitation were separated on nondenaturing gradient gels, and apoA-I-containing particles were detected by Western blotting with an anti-apoA-I antibody ( Figure 4C , data for Donor 1 is shown). Consistent with our ELISA data, incubation of plasma with CSL112 at 37°C resulted in a strong increase in concentration of HDL-VS (≈5.6 nm). Similar to the remodeling of CSL112 in rabbits ( Figure 2C ), we observed a transient accumulation of HDL species (≈7.6 nm) which were smaller than parent CSL112, and then a size enlargement of particles present within medium HDL and HDL-L range pools. In contrast, native HDL caused only a slight increase in concentration of HDL-VS with no apparent changes in the distribution of medium HDL or HDL-L. Similarly, apoA-I did not alter the size distribution of larger HDL species.
CSL112 Enhances Cholesterol Esterification and Reduces Inflammatory Responses More Potently Than Native HDL
Having observed a strong difference between CSL112 and native HDL in their ability to potentiate the cholesterol capacity of plasma in vitro, we investigated whether CSL112 is also superior to native HDL in elevating human plasma LCAT activity and in modulating anti-inflammatory responses. The rates of cholesterol esterification catalyzed by LCAT after the addition of CSL112 or native HDL to pooled human plasma were compared in vitro. Plasma LCAT activity was dose dependently increased by CSL112, whereas native HDL had no effect on LCAT activity ( Figure 5 ).
We next assessed the anti-inflammatory properties of CSL112 and native HDL using human whole blood stimulated with phytohemagglutinin-M (PHA-M) for 20 hours as an in vitro model of inflammation. CSL112 (0.25-1 mg/ mL) caused an inhibition of PHA-induced upregulation of inflammatory adhesion molecule intercellular adhesion molecule 1 (ICAM1) (CD54) on both monocytes and neutrophils, whereas native HDL showed no measurable inhibitory effect ( Figure 6A ). CSL112 exerted even stronger inhibitory effects on the secretion of proinflammatory cytokines (tumor necrosis factor-α, interleukin-1β, and interleukin-6) and chemokines (IP-10, RANTES, and Mip-1β) in PHAstimulated human blood ( Figure 6B ). Compared with native HDL, ≈2-fold lower concentrations of CSL112 were required to achieve a similar extent of inhibition of tumor necrosis factor-α and interleukin-1β. Similarly, CSL112 strongly reduced secretion of RANTES, Mip-1β, IP-10, and interleukin-6, whereas inhibitory effect of native HDL was less pronounced (IP-10, RANTES) or absent (Mip-1β). The ability of CSL112 to mediate strong anti-inflammatory effects was further supported by the finding that CSL112 caused a strong reduction of the secretion of tumor necrosis factor-α and interleukin-1β in postinfused rabbit blood stimulated with PHA-M ex vivo ( Figure 6C ). . Time-dependent effects of pre incubation of human plasma with CSL112, native high-density lipoprotein (HDL), or apoA-I on the plasma capacity to efflux cholesterol and to generate very small (HDL-VS). CSL112, native HDL, or apoA-I was added to fresh human EDTA plasma from 2 normolipidemic subjects at concentration of 1 mg protein/mL and incubated at 37°C for 0, 5 min, 10 min, 30 min, 1 h, 4 h, and 18 h. Control plasma was supplemented with phosphate-buffered saline (PBS). A, HDL fractions were obtained after precipitation of plasma apoB lipoproteins with polyethyleneglycol and used for the measurements of cholesterol efflux from RAW264.7 cells. Final concentration of CSL112, native HDL, or apoA-I in efflux medium was 5 µg/mL; serum was at 0.45%. Each fractional cholesterol efflux value is the mean±SD of triplicate measurements. B, HDL-VS levels were measured in plasma samples by a specific ELISA (Sekisui/American Diagnostica GmbH). Values shown are mean±SD of duplicate measurements. C, HDL fractions obtained as described in A were subjected to nondenaturing gel electrophoresis on gradient 4% to 30% polyacrylamide gels followed by Western blot analysis with anti-apoA-I antibody. Data are shown for Donor 1.
Discussion
Here, we describe and characterize a formulation of hApoA-I designed to remove cholesterol from atherosclerotic plaques of coronary heart disease patients. CSL112 is a population of disc-shaped particles bearing 2 molecules of hApoA-I and ≈110 molecules of phospholipid (Figure 1 ). Its pharmacokinetic behavior in rabbits suggests that it avoids the rapid clearance of unformulated apoA-I (Figure 2A) . Coupled with its ability to accept cholesterol from cells ex vivo, these data suggest that it may be a favorable therapeutic candidate.
In the course of this work, we discovered that on infusion of CSL112 into rabbits or on addition of CSL112 into plasma, cholesterol efflux was enhanced to a greater extent than anticipated based on apoA-I content. Direct comparison with native HDL showed that it was ≈3-fold more potent than native HDL in enhancing cholesterol efflux (Figure 4 ). Further work showed that the increase in efflux was preferentially mediated by ABCA1 (Figures 2D, 3 , and 4A). We view this property as favorable because cellular cholesterol excess causes increased expression of ABCA1, and cholesterol withdrawal may, therefore, be targeted to cholesterol-rich tissues such as atherosclerotic plaque. Further characterization of the disproportionate rise in ABCA1-mediated efflux showed that it was seen in both normal and dyslipidemic plasma (Figure 3 ). Patients with low HDL and high triglyceride, such as those studied in Figure 3A , are at risk of coronary heart disease and are commonly seen in patients with ACS.
Active remodeling of CSL112 in plasma offers a mechanistic explanation for the preferential elevation of ABCA1dependent efflux. In the hours after infusion of CSL112 into rabbits, hApoA-I was observed in particles smaller than parent CSL112 (Figure 2E) , and the prevalence of these forms correlated with the rise in ABCA1-mediated cholesterol efflux. In vitro, <2% of the apoA-I in parent CSL112 reacts with an antibody against lipid-poor HDL-VS (PreBeta1-HDL; Figure 4B ). However, addition of CSL112 to human plasma caused dramatic elevation of HDL-VS ( Figure 4C ) with nearly half of the added apoA-I reactive in a HDL-VS ELISA ( Figure 4B ), again consistent with active remodeling of the CSL112 particle to lipid-poor species. Lipid-poor forms of apoA-I, such as HDL-VS, are the primary acceptors of cholesterol from ABCA1, whereas HDL-L and very large HDL are poor substrates, 13, 19 and thus remodeling to lipidpoor species may account for elevated ABCA1-mediated efflux, and further remodeling of apoA-I back into the main HDL fraction may account for the subsequent decline in ABCA1-mediated efflux.
Elevation of HDL-VS is thought to be beneficial in removing cholesterol from the artery wall. Waksman et al 20 tested this hypothesis by remodeling HDL in patient plasma ex vivo with a proprietary procedure and then reinfusing the plasma with elevated HDL-VS. Intravascular ultrasound measurements in monkeys 21 and humans 20 strongly suggested that this therapy reduced plaque size. In this setting, the total amount of apoA-I circulating in patients was not increased. These data suggest that elevation of HDL-VS by itself affects plaque. By extension, coupling HDL-VS elevation with net elevation of apoA-I should provide further benefit.
In the normal course of reverse cholesterol transport, unesterified cholesterol exits cells for incorporation into nascent HDL particles and is then promptly esterified by the action of LCAT. Esterification enables HDL to carry a much greater load of cholesterol. Moreover, by reducing the concentration of unesterified cholesterol on the surface of HDL, LCAT may prevent reuptake of unesterified cholesterol via scavenger receptor B1 or diffusion. 22, 23 On infusion of CSL112 into rabbits, we observed elevation of plasma unesterified cholesterol then prompt esterification ( Figure 2B ). These results are consistent with the observation of dose-dependent elevation of cholesterol esterification rate on addition of CSL112 to human plasma ( Figure 5 ). They differ, however, from results in mice where very little esterification of cholesterol was seen on infusion of a reconstituted HDL. 24 A potential explanation of the difference is the poor ability of hApoA-I to activate murine LCAT. 24 It is likely that 2 factors contribute to the degree of LCAT activity on adding CSL112 to human plasma. Human LCAT transfers the fatty acid at the sn-2 position of PC to cholesterol, with a marked preference for long chain length, unsaturated fatty acids. 25 The soy PC in CSL112 contains linoleic acid (18:2) as the dominant fatty acid, thus providing a favorable substrate. LCAT also requires allosteric activation by apoA-I and substrate particles of relatively small diameter, 26 and both of these features are present in CSL112.
A large literature supports the notion that HDL can have anti-inflammatory effects on a wide range of cell types. 27 The mechanisms underlying this activity are not fully known, but in several instances, the anti-inflammatory action of HDL can be explained through its withdrawal of cholesterol from cell membranes. 28, 29 For example, the action of HDL on monocytes can be recapitulated using cyclodextrin, a cholesterol-binding agent. 29 Consistent with this notion, it has been observed that cells deficient in ABCA1 and ATP binding cassette transporter G1 have excess membrane cholesterol and an exaggerated inflammatory response, which can in turn be normalized with cyclodextrin or HDL. 30 We observed that addition of CSL112 to whole human blood blunted the production of several cytokines in response to challenge with PHA ( Figure 6 ). ACS patients have heightened inflammatory activity, 31 and this strong anti-inflammatory activity of CSL112 may offer important benefits for these patients. Interestingly, CSL112 was significantly more potent than native HDL at inhibiting Cytokine expression is presented as percentage change from the levels observed in PHA-stimulated cells. ****P<0.0001, ***P<0.001, **P<0.01, and *P<0.05 (n=3) compared with PHA-stimulated cells. B and C, CSL112 inhibits the secretion of proinflammatory mediators. B, Heparinized human whole blood was stimulated as described in A. Cytokine production was measured in cellfree supernatants at 20 h after PHA stimulation. Results are derived from duplicate cell cultures of 3 donors. Cytokine expression is presented as percentage change from the levels observed in PHA-stimulated cells. Shown are mean±SD. ****P<0.0001, ***P<0.001, **P<0.01, and *P<0.05 (n=3) compared with PHA-stimulated cells. Neither CSL112 nor native HDL significantly affected expression of cytokines in PHA unstimulated cells even at the highest dose tested (1 mg/mL). C, CSL112 was administered to rabbits intravenously (dose 75 mg/kg, infusion period 0.7 h). Rabbit blood collected into NH 4 -heparin at different time intervals after infusion was stimulated as described above. Cytokine expression is presented as percentage change from the baseline levels detected in stimulated whole blood before CSL112 infusion. Values show the mean±SD for the 8 CSL112-treated animals. ****P<0.0001, ***P<0.001, and **P<0.005 (n=8) compared with baseline values (pre infusion).
inflammatory responses in monocytes and neutrophils in blood. A potential explanation for these differences may lie in the superior ability of CSL112 to support cholesterol efflux and HDL-VS generation ( Figure 4A and 4B) .
The steps involved in remodeling of CSL112 to HDL-VS are not clear at this time, but prior in vitro work suggests a possible path. 32, 33 These studies showed that incubation of reconstituted HDL discs with LDL and LCAT caused reduction in HDL particle size after 3 hours, an effect that presumably represents the formation of small spherical HDL. These particles then underwent LCAT-mediated fusion to create larger particles in the size range of HDL-L in a process that is accompanied by the dissociation of poorly lipidated apoA-I. The sequential size changes of hApoA-I after infusion in rabbits ( Figure 2E ) are consistent with this sequence; hApoA-I showed an initial slight decline in particle size followed by generation of larger particles in the size range of HDL-L. The larger particles promptly diminished in size and particles of very small size, presumably lipid-poor species, appeared. In the prior studies of Liang et al, 33 disc-shaped reconstituted HDL particles fused with one another to yield larger particles. In the studies described here, however, plasma supplies endogenous HDL particles, and thus fusion of CSL112 with native HDL may also occur.
Additional work will be required to understand the behavior of CSL112 infused in humans. It is clear that plasma does not have the cells or cell-bound lipases that can affect HDL remodeling over and above what is caused by LCAT, cholesterol ester transport protein, and phospholipid transfer protein. Moreover, rabbits represent an imperfect model because of their deficiency in hepatic lipase. 34 Nevertheless, our studies, coupled with the recent observation of a strong correlation between cholesterol efflux capacity and risk of coronary disease, 35 encourage further development of interventions, such as CSL112, that can favorably affect cholesterol efflux capacity, as well as cholesterol esterification and inflammation.
